Results 241 to 250 of about 187,291 (347)

Airway Resistance Caused by Sphingomyelin Synthase 2 Insufficiency in Response to Cigarette Smoke. [PDF]

open access: yesAm J Respir Cell Mol Biol, 2020
Gupta G   +17 more
europepmc   +1 more source

Endoplasmic reticulum stress and the unfolded protein response in lung diseases: molecular pathways and therapeutic interventions

open access: yesThe Journal of Pathology, EarlyView.
Abstract Endoplasmic reticulum stress (ERS) occurs when the protein‐folding capacity of the endoplasmic reticulum (ER) is overwhelmed, triggering the unfolded protein response (UPR) to restore homeostasis. However, severe or persistent ERS can shift the UPR toward pro‐inflammatory, apoptotic, and fibrotic signaling, thereby exacerbating tissue injury ...
Lanlan Song   +6 more
wiley   +1 more source

Diagnosis and treatment of flow limitation with a controllable airway resistance - a software simulation

open access: diamond, 2016
Bernhard Laufer   +4 more
openalex   +1 more source

Long term oral appliance therapy decreases stress symptoms in patients with upper airway resistance syndrome. [PDF]

open access: yesJ Clin Sleep Med, 2020
de Godoy LBM   +7 more
europepmc   +1 more source

A Comprehensive Review of the Genetic Etiology and Management of Orofacial Clefts

open access: yesPediatric Discovery, EarlyView.
ABSTRACT Cleft lip (CL) and cleft palate (CP), collectively referred to as orofacial clefts (OFCs), are among the most common birth defects and can have significant effects on speech, nutrition, and physical and psychosocial development. Manifestation, classification, and treatment plans of OFCs are diverse and not standardized.
Emily Kim   +3 more
wiley   +1 more source

A Study of Nasal Airway Resistance and Nasal Airflow in Augmentation Rhinoplasty

open access: green, 1997
Perapun Jareoncharsri   +3 more
openalex   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

open access: yesRespirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Home - About - Disclaimer - Privacy